Epi Notes by South Carolina Department of Health and Environmental Control, Bureau of Disease Control
             Vol. XXV  Issue No.  2 June 2004
(see CHLAMYDIA on page 3)      (see  WEST NILE VIRUS  page 3)
Report on the Enhanced Surveillance for Chlamydia
in Women - South Carolina, 1998-2002
 WAYNE A. DUFFUS, MD, PhD
Medical Consultant
Extent of Chlamydia Problem
Chlamydia remains a significant health threat among
women and adolescents.  Most estimates predict that 1 in 20
sexually active woman of childbearing age or 1 in 10 adoles-
cent girls are infected with chlamydia.  In fact, 90% of all
reported cases are in individuals less than 24 years of age.
Unfortunately, 60 – 80% of infected women have no symp-
toms, and therefore are not aware of their infection and may
not seek health care.
Chlamydia is the most commonly reported sexually
transmitted infection among women in the United States (US).
The southeast led the nation in chlamydia prevalence in 2002.
For example, there were 451.1 cases/100,000 persons diag-
nosed in the U.S. but 604.3 cases/100,000 persons diagnosed
in South Carolina (SC) in that year.  Because of this high
prevalence in our state, the SC Department of Health and
Environmental Control (DHEC) began screening at sentinel
sites in 1996, and implemented statewide screening by 1998.
When diagnosed, chlamydia can be easily treated and
cured.  An untreated infection has severe and costly compli-
cations including pelvic inflammatory disease (PID), ectopic
pregnancy, infertility, chronic pelvic pain and adverse preg-
nancy outcomes.  In addition, because this is an inflamma-
tory condition, an untreated woman is at increased risk of
acquiring HIV via sexual transmission from an HIV-infected
sex partner.
Addressing the Problem
In recognition of this major public health problem, SC
participates in the Region IV Chlamydia Prevention Project
(Alabama, Florida, Georgia, Kentucky, Mississippi, North
Carolina, and Tennessee), a publicly funded program to sup-
port chlamydia screening primarily in family planning (FP)
clinics, but also sexually transmitted disease (STD) clinics,
prenatal clinics, jail, juvenile detention centers, and other sites.
All county health departments follow the state STD
Program Standing Orders for treatment, and partner treatment
West Nile Virus - 2003 Summary and
the Upcoming Season
LENA M. BRETOUS, MD, MPH
Medical Consultant
In 2003, South Carolina recorded six human cases of
West Nile Virus (WNV). Surveillance numbers for other WNV
positives in 2003 include:  282 birds, 54 equine, 3 mosquito
pools, and 1 alpaca.  See table on page
three for human case description.
Because of the long stretch of
warm weather in spring and fall, in-
fected mosquitoes have a longer win-
dow to spread the disease in South
Carolina.  The first human WNV case
in South Carolina during 2003 was also
the first recorded case in the country
last year. The last case of the season in
SC occurred in late November.  Activ-
ity has already been recorded for 2004
in some parts of the country.
Though most infected individu-
als are asymptomatic, roughly 20 per-
cent show self-limited viral symptoms
of fever, malaise, and muscle aches last-
ing several weeks.  According to CDC
guidelines, diagnosis of WNV infec-
tion is based on a high index of clinical
suspicion and obtaining specific labo-
ratory tests.
? WNV, or other arboviral diseases such as St.
Louis encephalitis, should be strongly
considered in adults >50 years who develop
unexplained encephalitis or meningitis in
summer or early fall.
? The local presence of WNV enzootic activity or
other human cases should further raise suspicion.
? Obtaining a recent travel history is also important.
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Update on Foodborne Illness in S.C.
 JULIE SCHLEGEL,  MSP
  Foodborne Epidemiologist
The Centers for Disease Control and Prevention (CDC)
estimates that each year 76 million people get sick, more than
300,000 are hospitalized, and 5,000 die as a result of foodborne
illnesses.  With an increase in travel and outdoor-related ac-
tivities in the upcoming summer months, ideal conditions for
the growth and proliferation of the foodborne pathogens are
enhanced. Vigilance for foodborne illness is especially im-
portant in diagnosing gastrointestinal illness.
Physicians play a vital role in alerting the public health
system about a potential foodborne outbreak by recognizing
suspicious symptoms, disease clusters, and etiologic agents,
and reporting illnesses to DHEC.  Proper collection of stool
specimens will also aid in diagnosis.  Close collaboration be-
tween the private and public health sectors is critical to the
foodborne outbreak investigation process.  This close work-
ing relationship between South Carolina providers and DHEC
has resulted in many successful investigations and identifi-
cation of causative organisms in foodborne illness over the
past few months.  Among these are the following:
• In October 2003, a cluster of Salmonella Enteritidis
was traced back to a large institutional setting,
thanks to astute  local providers who submitted stool cul-
tures to the DHEC Bureau of Laboratories for Pulsed Field
Gel Electrophoresis (PFGE) testing.
• In November 2003, an outbreak of Noro virus (for-
merly known as Noro-like virus) associated with a medical
seminar involving attendees from all over the southeast
was identified due to the timely collection of stool speci-
mens for culture and epidemiological investigation.
• In January 2004, an alert emergency department phy-
sician contacted DHEC regarding a cluster of diarrheal
illnesses seen in teenagers. This timely notification led to
the identification of an outbreak of Staphylococcus aureus
related to lasagna served in an institutional setting.
• In March 2004, a large outbreak of foodborne illness
caused by Clostridium perfringens in a catered meal was
successfully identified due to the timely collection and
PFGE testing of stool specimens and food samples.
A quick reference guide for foodborne etiological agents
is included on page six of this issue.  For consultation regard-
ing foodborne illnesses, please contact your local health de-
partment or the DHEC Division of Acute Disease Epidemiol-
ogy at (803) 898-0861.
A guide outlining sample collection and testing is avail-
able on our web page at:
http://www.scdhec.gov/hs/diseasecont/disease.htm
Vibrio vulnificus
Vibrio vulnificus is a rare but potentially deadly dis-
ease associated with the consumption of raw and undercooked
shellfish.  Infections are seasonal; over 85% occur between
May and October. Environmental factors, such as warm water
and moderate salinity, can increase the number of V. vulnificus
organisms in shellfish.  In 2003, three cases of Vibrio vulnificus
were reported to DHEC.  Two of the cases were fatal.  This
article is meant to provide healthcare providers with informa-
tion regarding Vibrio vulnificus and with tips to advise pa-
tients who have underlying risk factors for the disease.
Vibrio vulnificus is a naturally occurring estuarine or-
ganism. Shellfish, such as oysters, which feed by filtering
seawater that may contain Vibrio vulnificus are likely to be
infected with the organism. This is especially true of shellfish
harvested from the Gulf Coast region, where the majority of
cases in the United States occur.  Since much of the shellfish
imported into South Carolina comes the Gulf, Vibrio vulnificus
is a significant concern to our residents and tourists.
Vibrio vulnificus may cause vomiting, diarrhea, and ab-
dominal pain among healthy people who eat contaminated
seafood.  However, in patients with existing illness or those
who  are immunocompromised, Vibrio vulnificus can lead to
septicemia, causing a severe and life-threatening illness.  Vibrio
vulnificus bloodstream infections are fatal about 50% of the
time.  Persons at high risk for Vibrio vulnificus infection are
those with liver disorders (e.g. cirrhosis, hemochromatosis,
chronic hepatitis), diabetes, stomach disorders, cancer, HIV/
AIDS, and alcohol abuse, as well as those with a weakened
immune system due to a variety of medical treatments, such
as chemotherapy. Physicians are encouraged to warn their
patients with these risk factors to avoid eating raw or
undercooked shellfish. South Carolina is one of twenty states
that require reporting of Vibrio infections. Reports of Vibrio
cases can be phoned to your local health department or sub-
mitted by a DHEC Disease Report Card.
Furthermore, food safety education is a critical part of
the prevention of foodborne illness. DHEC has developed a
brochure on Vibrio vulnificus, which is available at your local
county health department or refer to the following sources for
more information and educational materials:
    Partnership for Food Safety Education
http://www.fightbac.org
CDC’s Food Safety Office
http://www.cdc.gov/foodsafety/
FDA Center for Food Safety and Applied Nutrition
http://www.cfsan.fda.gov
Food Safety.gov provides links to selected government food safety-
related information
http://www.foodsafety.gov
( see FOODBORNE ILLNESS - page 6)
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and referral.  A specially designed lab reporting form was com-
pleted for each woman and some of the information obtained is
being presented here.
Primary Objectives
The objective of this ongoing enhanced surveillance sys-
tem program is to determine the prevalence of chlamydia in
women attending DHEC FP and STD clinics and to monitor the
epidemiologic trends.  We also examined the potential impact of
this statewide screening and treatment on the incidence of PID
in SC.
Methods
Following the Center for Disease Control and Prevention
(CDC) recommendations, all women were tested who presented
to DHEC FP and STD clinics for care and were <24 years old and
also women who were >25 years old  with symptoms or any of
the following risk factors: history of STD, multiple partners,
recent new partner or sex without a condom.  DHEC provided
treatment and partner referral for those women with positive
test results.  Of all women, approximately 70% attend the FP
clinic & 30% attend the STD clinic.  The racial/ethnic mixture is
55% black, 40% white, and 5% Hispanic.
Gen-Probe DNA nucleic acid hybridization assay for all
women tested was done at the SC Public Health laboratory and
both positive and negative results were reported.  Women with
indeterminate or unsatisfactory results were excluded from the
final data analysis.
We defined a case as a positive chlamydia test result in a
woman who attended a DHEC FP/STD clinic during 1998-2002
and met criteria for testing.
The data source for PID incidence was obtained from the
statewide Hospital Inpatient Discharge Database and the Emer-
gency Department (ED) Database and the SC Budget and Con-
trol Board collect this information routinely.  Any primary diag-
nosis of PID during 1998-2002 in a woman residing in SC was
counted.
Figure 1.  Chlamydia Tests Performed Yearly
1) The number of women increased each year from 1998 to
2002.
2) The number of positive results obtained has remained
relatively constant among all groups.
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Figure 2.  Chlamydia Prevalence by Year
Prevalence rates for chlamydia have continued to decline
since the inception of the screening and treatment program.
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(CHLAMYDIA continued from page 1)
Updated information on clinical presentation, diagnostic
testing available through DHEC, specimen submission and re-
porting, and links to other sources are available on the DHEC
website at http://www.scdhec.gov/news/westnile/index.htm
A notable change from last year’s guidelines involves the
specimen size required for testing.  Specimen size has increased
from 1.0 cc to 1.5cc for CSF samples sent to commercial and
private labs.  The increase will ensure sufficient amount for
additional verification testing by the DHEC lab for suspect West
Nile encephalitis cases.
Submitting Specimens and Reporting WNV Suspects
and Cases: Physicians should contact their local County Health
Department’s Epidemiology staff or the Division of Acute Dis-
ease Epidemiology at 803-898-0861 or  888-847-0902 (after hours
and on weekends) to report confirmed or suspect cases of WNV
and to request laboratory testing by SC DHEC. For patients
meeting the clinical criteria, arrangements can then be made for
WNV testing by the DHEC Laboatory.
WNV Human Cases by County 2003
1 elderly male WN fever Oconee
2 adult males Meningoencephalitis Lexington
1 adult female Meningoencephalitis Berkley
1 adult male WN fever Orangeburg
1 adult male WN fever Jasper
(WEST NILE VIRUS - continued from page 1)
                            (see  CHLAMYDIA  page 4)
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Figure 3.  Chlamydia Cases by Age Group
The 15-19 year age group and the 20-24 year age group,
represents the largest numbers of women screened and treated.
Figure 4.  Chlamydia Prevalence by Age Group
1) The age group <19 years has the highest
prevalence.
2) Prevalence continues to decrease in the 20-24
year age group.
3) Older age group (>29 years) has the lowest
prevalence.
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Figure 5.  Chlamydia Prevalence by Race/Ethnicity
1) The prevalence has decreased for blacks from 1998
to 2002.
2) The prevalence among black women seen in DHEC
clinics is higher than for white/Hispanic women.
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Figure 6.  Impact of Chlamydia Screening on PID
1)    Chlamydia screening at sentinel sites may account
for the initial decline in incidence of ED PID
diagnoses.
2)     Further decline of ED PID diagnoses occurred with
implementation of statewide screening.
3)     The plateau in ED PID diagnoses may be due to the
other causes of PID which were not investigated
as part of this study.
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Limitations of the Data
Specifically, data are limited to women attending DHEC
clinics only.  In particular, chlamydia prevalence in this study
underestimates overall SC prevalence.  Also, chlamydia rates
in age and racial/ethnic subgroups may not be generalizable
to other populations in SC.
We are further limited in our inferences since the PID
data source cannot identify DHEC attendees and is limited
to diagnoses made in the ED/inpatient setting.
Conclusions
1) Chlamydia prevalence and PID incidence in SC
women declined during 1998 to 2002.
2) Chlamydia infection rates were highest in 10-19
year age group and in black women.
3) Universal screening in women aged <24 years at
DHEC FP/STD clinics is effective in decreasing
chlamydia prevalence.
4) Expansion of screening from sentinel sites to
statewide program further contributed to
decreased prevalence.
Summary
The data outlined in this article provides convincing
evidence that widespread screening and treatment of this
infection can reduce the prevalence of chlamydia in SC and
the consequent complications.  DHEC strongly recommends
chlamydia screening of sexually active women aged <24 years
in non-DHEC healthcare settings as part of routine annual
examination.  DHEC will continue to promote targeted pre-
vention efforts for young women and black women, because
chlamydia prevalence remains high in these groups.
The information provided in this enhanced surveil-
lance for chlamydia with screening and treatment is more
complete than the already existent passive surveillance sys-
tem.  The latter has been the standard for years and is re-
quired by DHEC SC Code of Law 44-1-80 and Regulation 61-
20 for the reporting of communicable diseases.  The passive
system includes both men and women diagnosed with
chlamydia but are limited in that some cases are likely tested
only if symptoms are present.  It also depends on timely
reprting from laboratories of positive cases.  In addition, the
passive reporting system is not representative of the entire
SC population as it only includes reports of positive tests of
patients from all providers, but does not provide for com-
parative studies, any information about those individuals
who test negative.  The enhanced surveillance system in the
DHEC clinices offers the advantage of 100% reporting of
both positive and negative results to allow for calculation of
prevalence.
The program would benefit from increased funding to
allow expansion to other at risk groups.  In 2001 the program
was expanded to include testing in men and is greatly facili-
tated by the availability of urine-based testing.  Up to 50% of
men who are infected with chlamydia are asymptomatic and
thus there is a large number of unidentified, infected indi-
(CHLAMYDIA continued from page 4)
Here in the Division of Acute Disease Epi, we receive
questions on a regular basis from providers regarding epide-
miology and public health issues. We recognize that some of
the questions may be of interest for a wider audience, so we
are introducing an “Ask Epi” column to Epi Notes.  A few
questions will be selected and included in each issue with
responses from our medical consultants.
Please email questions to: AskEpi@sc.dhec.gov.  Please
note that emails sent to this address will not take the place of
consultations with DHEC public health professionals regard-
ing specific cases or issues.
QUESTION:  IgM Positive or Not? Our practice recently
saw a pre-school child with a febrile rash illness for whom
diagnostic evaluation included a test for measles IgM
antibodies.  The private lab which handles our specimens
reported the IgM test as positive, but the reference DHEC
lab reported a negative IgM on a repeat serum drawn four
days later by a public health nurse who was following-up on
the presumptive diagnosis of measles. This suggests that
the initial positive IgM was a “false-positive”.  Please
comment!
ANSWER  provided by Eric Brenner, MD: For  many diseases
IgM antibodies constitute the early immunologic response
and a positive IgM result thus often assists clinicians not
only in making a diagnosis but in confirming the recent onset
of infection and/or illness.   In addition, for purposes of
public health surveillance, the detection of IgM antibodies
is often an essential prerequisite to the “case confirmation
process” which is at the basis for reporting communicable
disease incidence from SC DHEC to the US Centers for
Disease Control (CDC) — a process essential for monitoring
communicable disease trends in the United States.  For
example, positive IgM antibody test results are part of  the
formal “case definitions” used for arbovirus infections
                                 (see  ASK EPI  page 7)
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
viduals who are capable of transmitting the infection to their
sexual partners.  These urine-based tests will also allow diag-
nosis in places where it is difficult to performed a pelvic ex-
amination, such as in a community outreach setting in high
prevalence areas.
Altogether, this enhanced screening and surveillance
is providing a significant impact on the prevalence of chlamy-
dia and the incidence of PID in South Carolina.
Ask
Epi
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( FOODBORNE ILLNESS continued from  page 2)
The following table lists some etiologic agents to consider for various manifestations of foodborne illness.  This 
table is contained in Diagnosis and Management of Foodborne Illnesses: A Primer for Physicians and Other Health 
Care Professionals. A free copy of the primer is available at: 
http://www.ama-assn.org/ama/pub/category/3629.html 
 
 
Clinical Presentation Potential Food-Related Agents to Consider 
Gastroenteritis (vomiting as 
primary symptom; fever and/or 
diarrhea also may be present) 
Viral gastroenteritis, most commonly rotavirus in an infant or norovirus and other 
caliciviruses in an older child or adult; or food poisoning due to preformed toxins (eg, 
vomitoxin, Staphylococcus aureus toxin, Bacillus cereus toxin) and heavy metals. 
Noninflammatory diarrhea 
(acute watery diarrhea without 
fever / dysentery; some patients 
may present with fever)* 
Can be caused by virtually all enteric pathogens (bacterial, viral, parasitic) but is a classic 
symptom of: 
Enterotoxigenic Escherichia coli 
Giardia 
Vibrio cholerae 
Enteric viruses (astroviruses, noroviruses and other caliciviruses, enteric adenovirus, 
rotavirus) 
Cryptosporidium 
Cyclospora cayetanensis 
Inflammatory diarrhea (invasive 
gastroenteritis; grossly bloody 
stool and fever may be 
present)? 
Shigella species 
Campylobacter species 
Salmonella species 
Enteroinvasive E. coli 
Enterohemorrhagic E. coli 
E. coli O157:H7 
Vibrio parahaemolyticus 
Yersinia enterocolitica 
Entamoeba histolytica 
Persistent diarrhea (lasting >14 
days) 
Prolonged illness should prompt examination for parasites, particularly in travelers to 
mountainous or other areas where untreated water is consumed. Consider Cyclospora 
cayetanensis, Cryptosporidium, Entamoeba histolytica, and Giardia lamblia. 
Neurologic manifestations (eg, 
paresthesias, respiratory 
depression, bronchospasm, 
cranial nerve palsies) 
Botulism (Clostridium botulinum toxin) 
Organophosphate pesticides 
Thallium poisoning 
Scombroid fish poisoning (histamine, saurine) 
Ciguatera fish poisoning (ciguatoxin) 
Tetradon fish poisoning (tetrodotoxin) 
Neurotoxic shellfish poisoning (brevitoxin) 
Paralytic shellfish poisoning (saxitoxin) 
Amnesic shellfish poisoning (domoic acid) 
Mushroom poisoning 
Guillain-Barre syndrome (associated with infectious diarrhea due to Campylobacter jejuni) 
Systemic illness (eg, fever, 
weakness, arthritis, jaundice) 
Listeria monocytogenes 
Brucella species 
Trichinella spiralis 
Toxoplasma gondii 
Vibrio vulnificus 
Hepatitis A and E viruses 
Salmonella Typhi and Salmonella Paratyphi 
Amebic liver abscess 
 
*Noninflammatory diarrhea is characterized by mucosal hypersecretion or decreased absorption without mucosal destruction and generally 
involves the small intestine. Some affected patients may be dehydrated because of severe watery diarrhea and may appear seriously ill. This is 
more common in the young and the elderly. Most patients experience minimal dehydration and appear mildly ill with scant physical findings. 
Illness typically occurs with abrupt onset and brief duration. Fever and systemic symptoms usually are absent (except for symptoms related 
directly to intestinal fluid loss).  
?Inflammatory diarrhea is characterized by mucosal invasion with resulting inflammation and is caused by invasive or cytotoxigenic microbial 
pathogens. The diarrheal illness usually involves the large intestine and may be associated with fever, abdominal pain and tenderness, 
headache, nausea, vomiting, malaise, and myalgia. Stools may be bloody and may contain many fecal leukocytes. 
Digitized by South Carolina State Library
Epi Notes            Page 7 June 2004
(ASK EPI  continued from page 5)
(including WNV), measles, mumps, rubella, hepatitis A and
hepatitis B (IgM anti-HBcAg) (1,2).   Nonetheless, as your
case illustrates, IgM tests, like all tests, are not perfect and
may give false positive results.   This point is also illustrated
through the following two brief case reports.
Case 1:  A 39 year old male from Lexington County had
onset of fever, malaise, and myalgia in summer 2003 at a time
when WNV was very much in the news.   Diagnostic evalua-
tion included a test for WNV IgM which was reported as
positive by a private laboratory.  A repeat test performed at
the DHEC laboratory was IgM negative.  At the same time
the patient’s febrile illness persisted longer than would be
expected for “West Nile Fever”.  It was concluded that the
patient did not have an acute WNV syndrome and should
not be counted as a SC case or reported to CDC.
Case 2:  An asymptomatic 32 year old female from
Richland County was tested in the summer of 2003 for hepa-
titis B surface antigen as part of a routine pregnancy evalua-
tion.  The test for HBsAg was performed as part of a “hepa-
titis panel” which reported a positive test for IgM antibodies
to the hepatitis A virus.  A repeat IgM anti-HAV test at the
DHEC laboratory was reported as “equivocal”.  Liver func-
tion tests performed at the same time were all within normal
limits.   Further questioning revealed that five months earlier,
the patient, her husband and two young daughters had ex-
perienced a “viral syndrome” which, while not specific for
any particular illness, was compatible with a mini intra-fam-
ily-outbreak of hepatitis A.   It was concluded that the patient
did not have acute hepatitis A, and that it was possible —
though not confirmed — that traces of IgM remained in her
blood from an acute HAV infection she had had at the begin-
ning of the year.  Thus the patient’s contacts did not need to
receive prophylactic IG, she was not counted as a case, and
not reported to CDC.
Comment:   False positive IgM tests may occur for a number
of reasons:
• recent vaccination -  for example recent administration
of live attenuated MMR vaccine would produce IgM
antibodies against measles, mumps and rubella.  A febrile
rash illness occurring two or three months later might
thus, because of the persisting IgM, be misconstrued
as measles unless a careful history had obtained
information about the recent MMR vaccination.
• unusually long persistence of IgM antibodies: for
example it is now recognized that IgM in some arbovirus
infections, including WNV, can persist not just for a
few weeks or months, but even for the better part of a
year or more.  Thus it might be wrongly concluded that
a patient had acute West Nile Fever because of a
clinically compatible illness accompanied by a positive
WNV IgM test, whereas in fact the IgM may simply
have resulted from an asymptomatic WNV infection
acquired months before during the preceding year’s
mosquito season.
• IgM tests, like all other tests, are not 100% specific,
and because of immunologic cross-reactions, problems
with laboratory technique, and/or other sometimes
poorly understood factors, may simply yield positive
results when they ought not too.  While not frequent,
such occurrences are well documented in the literature
(3-6).
Since most positive IgM tests performed by compe-
tent laboratories are undoubtedly true positives, there is
clearly no need to confirm all positive results.   In general
confirmatory testing is desirable if (i) the clinical picture and/
or epidemiologic reality are not consistent with the presump-
tive serological diagnosis, and / or (ii) the disease is of such
public health importance that even the occurrence of a single
case needs to be confirmed using the most refined and care-
fully controlled laboratory methods.  Such methods may only
be available in a reference laboratory such as the DHEC state
lab which works in close collaboration with CDC’s own na-
tional reference laboratory network.
In the case you describe in your question, it was cer-
tainly appropriate to take steps necessary to confirm or dis-
prove the diagnosis of measles.  The context  for this extra
effort being is that transmission of domestic measles virus
has been interrupted in the United States (7); the country is
in measles elimination mode; and every single suspect case
thus needs to be confirmed.  In addition, measles, following
the example of smallpox, and hopefully soon following the
example of poliomyelitis (8) is already being proposed as the
next target disease for global eradication (9).
References:
1. See Case Definitions for public health at:  www.cdc.gov/epo/
dphsi/casedef/case_definitions.htm
2. CDC. Case Definitions for Infectious Conditions Under Public
Health Surveillance. MMWR / Vol. 46 / No. RR-10 May 2,
1997).
3. Donovan SM.. False-positive results of an enzyme immunoassay
for rubella IgM in a case of measles. Clin Infect Dis. 1997
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4. False positive rubeola IgM tests . N Engl J Med. 1995 Apr
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5. False positive tests for rubella-specific IgM. Pediatr Infect Dis
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